Chapter 7: Problem 4
When might it be a disadvantage to inhibit a drugdestroying enzyme?
Chapter 7: Problem 4
When might it be a disadvantage to inhibit a drugdestroying enzyme?
All the tools & learning materials you need for study success - in one app.
Get started for freeResistance to your new potent antibacterial drug (1) was shown to be the result of a single-point genetic mutation in the target enzyme such that an important active site lysine residue was mutated to an aspartate residue. Suggest a simple way to proceed toward the design of a new antibacterial drug against the resistant strain.
Augmentin is a medicine that combines amoxicillin, a \(\beta\)-lactam antibiotic, with clavulanate, a \(\beta\)-lactamase inhibitor. Why is it important that the two compounds have similar pharmacokinetics (e.g., oral bioavailability and plasma half-life) in humans?
One mechanism of drug resistance is that the organism has a genetically altered enzyme. How does this lead to drug resistance?
If drug resistance to an antibacterial compound arises from expression of a new enzyme in the resistant organism that destroys the drug, what three approaches could you take to combat the resistance?
What do you think about this solution?
We value your feedback to improve our textbook solutions.